ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements
Skybiotech Healthcare Ltd reported revenue from operations of ₹1 Cr (-47.4% YoY) and a net loss of ₹0.8 Cr for Q2 FY27.
Skybiotech Healthcare Ltd has scheduled a board meeting for November 10, 2026. The board will consider unaudited financial results for the quarter ended September 30, 2026.
This is a routine quarterly shareholding pattern filing for Skybiotech Healthcare Ltd in compliance with SEBI Regulation 31(1)(b).
Skybiotech Healthcare Limited held its 43rd Annual General Meeting on September 30, 2026. Shareholders approved audited financial statements, director re-appointment, and the appointment of statutory auditors.
Skybiotech Healthcare Ltd has issued the notice for its 43rd Annual General Meeting. The meeting is scheduled to be held on September 30, 2026.
Skybiotech Healthcare Ltd has filed its Annual Report for the financial year 2025-26, pursuant to Regulation 34 of the SEBI LODR Regulations.
Skybiotech Healthcare Ltd reported revenue from operations of ₹0.5 Cr (-79.2% YoY) and a net loss of ₹0.6 Cr for Q1 FY27.
Skybiotech Healthcare Limited has scheduled a board meeting for August 14, 2026. The board will consider and approve un-audited financial results for the quarter ended June 30, 2026.
Skybiotech Healthcare Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, as required by SEBI regulations.
Skybiotech Healthcare Ltd has filed its quarterly shareholding pattern statement as per regulatory requirements. This document details the company's equity distribution across various shareholder categories.
Skybiotech Healthcare Ltd reported revenue from operations of ₹1.8 Cr (+80.0% YoY) and a net loss of ₹0.3 Cr for Q4 FY26.
Skybiotech Healthcare Limited approved its audited standalone and consolidated financial results for the fiscal year ending March 31, 2026. The board meeting concluded with an unmodified audit opinion.
Skybiotech Healthcare scheduled a board meeting for May 30, 2026, to approve audited annual financial results. The meeting will review the period ending March 31, 2026.
Skybiotech Healthcare Ltd disclosed its status under the SEBI Large Corporate framework for FY 2026. The company reported zero outstanding borrowings as of March 31, 2026, confirming it does not meet the criteria for mandatory debt market sourcing.
Skybiotech Healthcare Ltd reported a net loss of ₹0.5 Cr for Q3 FY26.